Regular Article
Hammerhead Ribozymes Targeted to the FBN1 mRNA Can Discriminate a Single Base Mismatch between Ribozyme and Target

https://doi.org/10.1006/bbrc.1998.9241Get rights and content

Abstract

Hammerhead ribozymes are catalytic RNA molecules that can act intrans,with ribozyme and substrate being two different oligoribonucleotides with regions of complementarity. Mutations in the gene for fibrillin-1 (FBN1) cause Marfan syndrome. The majority of mutations are single-base changes, many of which exert their effect via a dominant-negative mechanism. Previously we have shown that an antisense hammerhead ribozyme, targeted to the FBN1 mRNA can reduce deposition of fibrillin to the extracellular matrix of cultured fibroblasts, suggesting it may be possible to utilize ribozymes to down regulate the production of mutant protein and thus restore normal fibrillin function. This might be achieved by the mutation creating a ribozyme cleavage site that is not present in the normal allele, however this is likely to limit the number of mutations that could be targeted. Alternatively, it might be possible to target the mutant allele via the ribozyme binding arms. To determine the potential of ribozymes to preferentially target mutant FBN1 alleles via the latter approach, the effect of mismatches in helix I of a hammerhead ribozyme, on the cleavage of fibrillin (FBN1) mRNA was investigated. A single base mismatch significantly reduced ribozyme cleavage efficiency bothin vitroandin vivo.The discrimination between fully-matched and mismatched ribozyme varied with the length of helix I, with the discrimination being more pronounced in ribozymes with a shorter helix. These data suggest that it should be possible to design hammerhead ribozymes that can discriminate between closely related (mutant and normal) target RNAs varying in as little as a single nucleotide, even if the mutation does not create a ribozyme cleavage site.

References (34)

  • J.J. Rossi

    TIBTECH

    (1995)
  • W. James

    Curr. Op. Biotech.

    (1995)
  • Y. Ohta et al.

    J. Invest. Dermatol.

    (1996)
  • H.C. Dietz et al.

    Genomics

    (1993)
  • W. James et al.

    Curr. Opin. Biotechnol.

    (1995)
  • T.R. Cech et al.

    Annu. Rev. Biochem.

    (1986)
  • J. Haseloff et al.

    Nature

    (1988)
  • O.C. Uhlenbeck

    Nature

    (1987)
  • K. Sarver et al.

    Science

    (1990)
  • P. Steinecke et al.

    EMBO J.

    (1992)
  • J.D. Thompson et al.

    Nature Medicine

    (1995)
  • S.A. Gibson et al.

    Mol. Biotechnol.

    (1997)
  • H. Weve

    Arch. Augenheilk.

    (1931)
  • R.E. Pyeritz et al.

    N. Eng. J. Med.

    (1979)
  • Tsipouras, P. Kilpatrick, M. W. 1995, Molecular Genetics of Inherited Eye Disorders, Harwood Academic Publishers,...
  • P. Tsipouras et al.

    N. Eng. J. Med.

    (1992)
  • Cited by (25)

    • Disruption of dengue virus transmission by mosquitoes

      2015, Current Opinion in Insect Science
      Citation Excerpt :

      Trans-cleaving ribozymes have endoribonuclease activity in the presence of divalent cations like Mg2+ and can also perform multiple turn-over kinetics enhancing their catalytic activity [60–62]. Several features make hRz attractive as synthetic anti-arboviral effectors: firstly, hRz are derived from plant viroids, therefore arbovirus vectors do not exhibit any natural resistance against hRz; secondly, the antiviral effect of hRz is mediated through the catalytic activity of the molecule itself and does not require additional host factors [63]; thirdly, typical hRz target sites are 18–19 nucleotides in length, allowing a relatively high target specificity, fourthly, hRz activity is not restricted to a particular cellular compartment; RNA in both the nucleus and the cytoplasm is efficiently attacked, fifthly, hRz exhibit a high degree of target specificity, as single nucleotide polymorphisms can diminish hRz target recognition and cleavage [64]. In mammalian cells, hRz have demonstrated significant replication inhibition of many medically important viruses including human immunodeficiency virus (HIV), DENV2, influenza A virus, and hepatitis C virus (HCV) [65,66••,67,68].

    • Ribozyme and peptide-nucleic acid-based gene therapy

      2000, Advanced Drug Delivery Reviews
    View all citing articles on Scopus

    Chadwick, D. J.Cardew, G.

    1

    Corresponding author: Dr. Michael W. Kilpatrick, Department of Pediatrics, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030. Fax: (860) 679 1355. E-mail:[email protected].

    View full text